A 71-year-old patient with atrial fibrillation has been on warfarin for 5 years and is being transitioned to apixaban. Current INR is 2.6 (therapeutic). Which actions should the nurse plan during the warfarin-to-apixaban transition? Select all that apply.
Select All That Apply
Choose your responses, then check the answer.
Explanation
Option 1 is correct because discharge teaching must cover bleeding precautions, missed doses, and the differences between apixaban and warfarin. Option 2 is correct because warfarin is stopped and apixaban is started when the INR falls below 2.0, following manufacturer guidance. Option 3 is incorrect because apixaban does not interact with vitamin K, so the dietary consistency required with warfarin is no longer needed. Option 4 is correct because routine INR monitoring is not used for apixaban, while renal function should be assessed at baseline and periodically. Option 5 is correct because warfarin and apixaban are not overlapped; concurrent therapy would increase bleeding risk.
The warfarin-to-apixaban transition is a focused patient-safety topic. Per the apixaban prescribing information, warfarin is stopped and apixaban started when the INR is below 2.0; there is no overlap or bridging because dual anticoagulation increases bleeding risk. Once apixaban is started, INR monitoring is no longer needed for anticoagulation management; instead, the team checks creatinine clearance at baseline and periodically because dose reduction is required at CrCl below 50 with other criteria. The patient education shifts substantially: vitamin K intake no longer matters because apixaban does not interact with dietary vitamin K, so the food restrictions taught for warfarin can be relaxed. New teaching emphasizes bleeding precautions, missed-dose rules (take if within 6 hours of scheduled time, otherwise skip), avoidance of NSAIDs and aspirin unless prescribed, and holding apixaban before invasive procedures per provider order.
A 71-year-old patient with atrial fibrillation on warfarin for 5 years is being transitioned to apixaban. Current INR 2.6. The nurse plans the transition.
Transition Rule — Per apixaban prescribing information: stop warfarin and start apixaban when the INR is below 2.0. No overlap or bridging — concurrent warfarin plus apixaban produces dual anticoagulation and unacceptable bleeding risk. Other DOACs (rivaroxaban, dabigatran, edoxaban) have similar transition thresholds.
Monitoring Shift — Warfarin: INR every 1–4 weeks. Apixaban: no INR. Instead, baseline and periodic creatinine clearance, baseline LFTs, and clinical surveillance for bleeding. Dose reduction at CrCl <50 plus age >80 or weight <60 kg or serum creatinine >1.5.
Education Reset — Patients transitioning from warfarin must be re-educated. Stop: "consistent vitamin K," "monthly INR." Start: "no dietary vitamin K restriction," "missed-dose rule (within 6 hr take, otherwise skip), bleeding precautions, hold for procedures." Confusion between old and new instructions is a high-risk discharge teaching gap.